SeaStar Medical Reports Positive Survival Findings in QUELIMMUNE Registry Analysis

The company said QUELIMMUNE-treated pediatric patients showed statistically higher survival at Day 60, Day 90 and hospital discharge than a comparator cohort. No device-related adverse events occurred, according to the provided text.